Although hormone therapy is standard management of BC patients with ER and/or PR expressing tumors, multi-drug resistance or ER acquired mutations are serious clinical problems that limit the use of standard therapeutic options (adriamycine, paclitaxel) [5]. This evidence concerns the gene PGR and breast cancer.